Cardiovascular disease in end-stage renal disease

被引:2
作者
Park, Jung Tak [1 ]
Oh, Hyung Jung [1 ]
Kang, Shin-Wook [1 ]
机构
[1] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea
来源
JOURNAL OF THE KOREAN MEDICAL ASSOCIATION | 2013年 / 56卷 / 07期
关键词
Chronic kidney failure; Cardiovascular diseases; Risk factors; Biological markers; CHRONIC KIDNEY-DISEASE; LEFT-VENTRICULAR HYPERTROPHY; HEMODIALYSIS-PATIENTS; DIALYSIS PATIENTS; RECEIVING HEMODIALYSIS; CARDIAC BIOMARKERS; DIABETES-MELLITUS; RISK-FACTORS; DEATH RISK; FOLLOW-UP;
D O I
10.5124/jkma.2013.56.7.576
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The number of end-stage renal disease (ESRD) patients is progressively growing with more than 60,000 ESRD patients on renal replacement therapy in Korea. The mortality risk in ESRD patients is approximately 10 to 20-fold higher compared to the general population, which is mainly attributed to prevalent cardiovascular disease in these patients. However, the risk factors for cardiovascular disease in ESRD patients are different from the general population, and useful biomarkers for predicting cardiovascular mortality are not completely defined. The nationwide multicenter Clinical Research Center (CRC) for ESRD program was initiated in Korea not only to elucidate the incidence and prevalence of cardiovascular disease in ESRD patients but also to identify potential risk factors including various biomarkers for cardiovascular disease. A prospective cohort of 864 incident hemodialysis patients, from 34 dialysis centers of the CRC for ESRD in Korea, was followed up for 36 months, and the clinical outcome of these patients was reviewed. This article presents the recent data from the CRC for ESRD program, and, in addition, brief reviews on key risk factors and potential biomarkers for cardiovascular disease in ESRD patients.
引用
收藏
页码:576 / 582
页数:7
相关论文
共 35 条
  • [1] [Anonymous], 1997, Am J Kidney Dis, V30, pS67
  • [2] The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
    Baigent, Colin
    Landray, Martin J.
    Reith, Christina
    Emberson, Jonathan
    Wheeler, David C.
    Tomson, Charles
    Wanner, Christoph
    Krane, Vera
    Cass, Alan
    Craig, Jonathan
    Neal, Bruce
    Jiang, Lixin
    Hooi, Lai Seong
    Levin, Adeera
    Agodoa, Lawrence
    Gaziano, Mike
    Kasiske, Bertram
    Walker, Robert
    Massy, Ziad A.
    Feldt-Rasmussen, Bo
    Krairittichai, Udom
    Ophascharoensuk, Vuddidhej
    Fellstrom, Bengt
    Holdaas, Hallvard
    Tesar, Vladimir
    Wiecek, Andrzej
    Grobbee, Diederick
    de Zeeuw, Dick
    Gronhagen-Riska, Carola
    Dasgupta, Tanaji
    Lewis, David
    Herrington, William
    Mafham, Marion
    Majoni, William
    Wallendszus, Karl
    Grimm, Richard
    Pedersen, Terje
    Tobert, Jonathan
    Armitage, Jane
    Baxter, Alex
    Bray, Christopher
    Chen, Yiping
    Chen, Zhengming
    Hill, Michael
    Knott, Carol
    Parish, Sarah
    Simpson, David
    Sleight, Peter
    Young, Alan
    Collins, Rory
    [J]. LANCET, 2011, 377 (9784) : 2181 - 2192
  • [3] The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
    Besarab, A
    Bolton, WK
    Browne, JK
    Egrie, JC
    Nissenson, AR
    Okamoto, DM
    Schwab, SJ
    Goodkin, DA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) : 584 - 590
  • [4] Epidemiology and pathophysiology of left ventricular abnormalities in chronic kidney disease: a review
    Cerasola, Giovanni
    Nardi, Emilio
    Palermo, Alessandro
    Mule, Giuseppe
    Cottone, Santina
    [J]. JOURNAL OF NEPHROLOGY, 2011, 24 (01) : 1 - 10
  • [5] Chung SJ, 1999, KOREAN J NEPHROL, V18, P284
  • [6] Chronic kidney disease and cardiovascular disease in the Medicare population
    Collins, AJ
    Li, SL
    Gilbertson, DT
    Liu, JN
    Chen, SC
    Herzog, CA
    [J]. KIDNEY INTERNATIONAL, 2003, 64 : S24 - S31
  • [7] 장태익, 2004, Kidney Research and Clinical Practice, V23, P577
  • [8] Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
    Fellstroem, Bengt C.
    Jardine, Alan G.
    Schmieder, Roland E.
    Holdaas, Hallvard
    Bannister, Kym
    Beutler, Jaap
    Chae, Dong-Wan
    Chevaile, Alejandro
    Cobbe, Stuart M.
    Groenhagen-Riska, Carola
    De Lima, Jose J.
    Lins, Robert
    Mayer, Gert
    McMahon, Alan W.
    Parving, Hans-Henrik
    Remuzzi, Giuseppe
    Samuelsson, Ola
    Sonkodi, Sandor
    Sueleymanlar, Gultekin
    Tsakiris, Dimitrios
    Tesar, Vladimir
    Todorov, Vasil
    Wiecek, Andrzej
    Wuethrich, Rudolf P.
    Gottlow, Mattis
    Johnsson, Eva
    Zannad, Faiez
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (14) : 1395 - 1407
  • [9] CLINICAL AND ECHOCARDIOGRAPHIC DISEASE IN PATIENTS STARTING END-STAGE RENAL-DISEASE THERAPY
    FOLEY, RN
    PARFREY, PS
    HARNETT, JD
    KENT, GM
    MARTIN, CJ
    MURRAY, DC
    BARRE, PE
    [J]. KIDNEY INTERNATIONAL, 1995, 47 (01) : 186 - 192
  • [10] Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: The dialysis outcomes and practice patterns study (DOPPS)
    Goodkin, DA
    Bragg-Gresham, JL
    Koenig, KG
    Wolfe, RA
    Akiba, T
    Andreucci, VE
    Saito, A
    Rayner, HC
    Kurokawa, K
    Port, FK
    Held, PJ
    Young, EW
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (12): : 3270 - 3277